Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Adam Eckert

Why Akebia Therapeutics Stock Is Soaring After Hours

Akebia Therapeutics Inc (NASDAQ:AKBA) shares are surging in Thursday's after-hours session after the company executed an agreement to terminate its Vadadustat collaboration and license agreements with Otsuka Pharmaceutical.

As a result of the termination of the agreements, Akebia will regain the rights for Vadadustat in the United States, Europe, China, Russia, Canada, Australia, and the Middle East. Otsuka will pay Akebia a $55 million settlement fee. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.